Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$511.53M+53.17%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Stephen W. Beard
- Sector
- Consumer Defensive
- Industry
- Education & Training Services
- Employees
- 4,754
- Beta
- 0.66
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 4.01
Financials
Revenue
$511.53M+53.2%Net Income
$67.43M+367.8%EBITDA
$111.70M+72.3%Free Cash Flow
$76.45MEPS (diluted)
$1.95+1672.7%Shares Outstanding (diluted)
34.57M-46.0%Operating Expenses
$192.59MCash & Debt
$222.22MReturn of Capital
$81.00MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $1.95B | $251.57M | $7.63 |
| 2025 | $1.79B | $232.68M | $6.27 |
| 2024 | $1.58B | $136.78M | $3.49 |
| 2023 | $1.45B | $96.93M | $2.27 |
| 2022 | $1.38B | $-162.49M | $-3.36 |
| 2021 | $906.90M | $76.91M | $1.50 |
| 2020 | $1.05B | $202.23M | $3.77 |
| 2019 | $1.01B | $128.77M | $2.20 |
| 2018 | $1.24B | $33.77M | $0.55 |
| 2017 | $1.21B | $122.28M | $1.87 |
| 2016 | $1.84B | $-3.17M | $-0.05 |
| 2015 | $1.91B | $139.90M | $2.08 |
| 2014 | $1.92B | $134.03M | $2.09 |
| 2013 | $1.96B | $106.79M | $1.66 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from CVSA's reported EPS growth of 12.4% a year over 13 years.
- EPS in 5 years
- $12.88
- Implied price
- $206.05
- Return from $109.13
- 13.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $102.44 — -6.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 14 | 16 | 18 | 20 |
|---|---|---|---|---|---|
| 2.4% | -2.3% | 0.7% | 3.5% | 5.9% | 8.2% |
| 7.4% | 2.4% | 5.6% | 8.5% | 11.1% | 13.5% |
| 12.4% | 7.2% | 10.6% | 13.6% | 16.3% | 18.7% |
| 17.4% | 12.0% | 15.5% | 18.6% | 21.4% | 24.0% |
| 22.4% | 16.7% | 20.4% | 23.7% | 26.6% | 29.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
60-14.29%Social Signal Score
Mentions (18)
- Newsfool.com·6d ago·Positive
Covista: 3 Key Takeaways for Long-Term Investors Covista raised full-year revenue guidance to between $2.06 billion and $2.095 billion. Total student enrollment grew 7.6% year over year to nearly 105,000 students.
View source ↗ - Newszacks.com·13d ago·Neutral
After Plunging 14.7% in 4 Weeks, Here's Why the Trend Might Reverse for Covista (CVSA) The heavy selling pressure might have exhausted for Covista (CVSA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
View source ↗ - Newszacks.com·19d ago·Positive
Here's Why Covista (CVSA) is a Strong Growth Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - News (RSS)seekingalpha·20d ago·Neutral
Covista Inc. 2027 Q1 - Results - Earnings Call Presentation
View source ↗ - Newsseekingalpha.com·23d ago·Neutral
Covista: Stronger Results Keep Me Bullish, But Cash Flow Needs To Improve Covista (CVSA) maintains a Buy rating as recent results reinforce confidence in business direction and profitability improvements, especially at Walden. Walden drives group performance with 14.1% revenue and 16.1% EBITDA growth, but Chamberlain's profitability remains flat amid expansion investments. Cash flow concerns arise as operating cash flow declines and provisions for credit losses rise faster than revenue, warranti…
View source ↗ - News (RSS)investing·24d ago·Neutral
Covista Q1 FY27 slides: enrollment growth drives guidance raise
View source ↗ - Newszacks.com·24d ago·Positive
Covista (CVSA) Beats Q1 Earnings and Revenue Estimates Covista (CVSA) came out with quarterly earnings of $2.19 per share, beating the Zacks Consensus Estimate of $1.9 per share. This compares to earnings of $1.75 per share a year ago.
View source ↗ - Newsseekingalpha.com·24d ago·Positive
Covista Inc. (CVSA) Q1 2027 Earnings Call Transcript Covista Inc. (CVSA) Q1 2027 Earnings Call Transcript
View source ↗ - Newsbenzinga.com·24d ago·Positive
Covista Q1 2027 Earnings Call Transcript Covista (NYSE:CVSA) reported first-quarter financial results on Thursday. The transcript from the company's first-quarter earnings call has been provided below.
View source ↗ - Newsbusinesswire.com·31d ago·Neutral
…g Nursing Education in the State with the Fewest Nurses per Capita SANDY, Utah--(BUSINESS WIRE)--Chamberlain University, the nation's largest school of nursing and a Covista institution, cut the ribbon today on its Salt Lake City campus, its first in Utah and 26th nationwide. The campus welcomes its first cohort of Bachelor of Science in Nursing (BSN) students on Oct. 26. To mark the opening, Chamberlain teamed up with Zachery Dereniowski, known as “MD Motivator” to more than 40 million follower…
View source ↗ - Newszacks.com·37d ago·Positive
Why Covista (CVSA) is a Top Momentum Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·38d ago·Positive
Why Covista (CVSA) is a Top Growth Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newszacks.com·60d ago·Positive
Here's Why Covista (CVSA) is a Strong Growth Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newszacks.com·67d ago·Positive
Covista (CVSA) is a Top-Ranked Value Stock: Should You Buy? Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newszacks.com·80d ago·Positive
Here's Why Covista (CVSA) is a Strong Momentum Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newszacks.com·81d ago·Positive
Here's Why Covista (CVSA) is a Strong Growth Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·97d ago·Positive
Here's Why Covista (CVSA) is a Strong Growth Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newsseekingalpha.com·100d ago·Positive
Covista: Strong Secular Growth And Operating Leverage Covista is rated BUY, driven by secular healthcare education demand and 12 consecutive quarters of enrollment growth. CVSA's Q4 saw revenue up 9.7% and adjusted EPS up 25.9%, with all segments showing positive operating leverage and margin expansion. Strong cash flows, a declining leverage ratio, and $238m in share repurchases reinforce balance sheet strength and shareholder returns.
View source ↗
Earnings
Wed, Jan 27(in 2 months)
Consensus estimate $2.18 per share
Typical surprise +11.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Oct 29$2.19 vs $1.83beat
- Thu, Aug 6$2.09 vs $1.89beat
- Thu, May 7$1.98 vs $1.73beat
- Wed, Jan 28$2.43 vs $2.19beat
- Thu, Oct 30$1.75 vs $1.58beat
- Thu, Aug 7$1.66 vs $1.53beat
Estimates and results for CVSA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CVSA officers and directors.
- Bought
- $3.8m
- Sold
- $10.3m
4 trades
17 trades
- Beard, Stephen W.sold
- Beard, Stephen W.sold
- Gangadharan Manjunathsold
- Beard, Stephen W.sold
- Phelan Robert J.sold
- Beck Douglas G.sold
- Beard, Stephen W.sold
- Phelan Robert J.sold
76 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CVSA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
